Rejuvenate Biomed NV, a Heusden-Zolder, Belgium-based biomedical company developing novel combination drugs for age-related diseases, raised EUR 15.7m in Series B funding.
The round was led by Rejuveron Life Sciences AG and Luxembourg-based Vesalius Biocapital.
The company intends to use the funds to is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Established in October 2017 by Ann Beliën, PhD, after nearly two decades of experience with Janssen Pharmaceutical companies of Johnson and Johnson, Rejuvenate is developing safe, proprietary, combination drugs that delay or prevent the onset of multiple age-related diseases, with a focus on the intersection between fundamental aging mechanisms and chronic conditions. The company has developed a proprietary in silico screening platform that uses an approach based on artificial intelligence and network biology to investigate dysregulated pathways in aging. With this platform, the company is able to evaluate if safe, marketed treatments can be used as synergistic drug combinations to impact upon these pathways, maintaining natural cellular resilience and postponing the onset of certain age-related diseases.
Its lead drug candidate RJx-01 is a novel, small molecule, combination product identified using the company’s in silico platform. RJx-01 is being developed for the treatment of acute and chronic sarcopenia, a muscle disease defined by the loss of muscle strength, quality, and mass.
Rejuvenate Biomed is a resident company of Johnson & Johnson Innovation, JLABS, a premier life sciences incubator program.
FinSMEs
12/10/2021